![ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1550-218x150.jpeg "Researchers Discover Molecular Pathway Involved in Immunotherapy Response")
![One of the major scientific crusades in oncology has been to identify and validate biomarkers associated with recurrent breast cancer. [iStock / royaltystockphoto]](https://www.clinicalomics.com/wp-content/uploads/2019/01/585-218x150.jpeg "Agendia Reports Positive Results in IMPACt Trial for Breast Cancer")
Agendia Reports Positive Results in IMPACt Trial for Breast Cancer
MammaPrint and BluePrint reclassified 40% of pathologically subtyped tumors, highlighting the need for an individualized, molecular subtyping profile in early stage breast cancer diagnosing for patients.
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Somatic Mutations at Root of Some Cancers Apparent Years Before Onset
The findings suggest that tumor development can span the entire lifetime of an individual, so the mutations that initiate cancer progression may arise decades before diagnosis.
Co-Diagnostics Seeks CE Mark for its COVID-19 Coronavirus Test
The test uses the company’s CoPrimer technology to detect the presence of ribonucleic acid (RNA) of the novel strain of coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome.
Triple Negative Breast Cancer Recurrence Prediction Method Developed
Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.
20 Molecular Diagnostics Companies to Watch
Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.
CRISPR Detectives: Startups seek to expand access to diagnostics with inexpensive CRISPR-based tests
CRISPR-Cas9 is best known for its powerful ability to make double-stranded breaks in DNA, allowing scientists to delete and edit genes with relative ease....
Illumina and the Broad Co-Developing Open-Source Secondary Analysis Software
Leading open-source tools, GATK and DRAGEN, are being combined to create a cutting-edge software suite for methods including small variant (SNV) and large variant...
10 Countries in 100K Genome Club
These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine
Breast Cancer Care After Genetic Testing Often Doesn’t Follow Guidelines
Tracking treatment trends is important as more women are receiving genetic testing when they are diagnosed with early-stage breast cancer and treatment options are expanding.
